AbbVie hep C combo fast-tracked in U.S. and EU; Merck's Gardasil wins new indication in Europe;

> AbbVie's ($ABBV) all-oral hep C combo has won expedited assessment in both the U.S. and the EU. Report | Article

> Europe has approved Merck's ($MRK) Gardasil vaccine to prevent anal cancer. Report

> Bristol-Myers Squibb's ($BMY) "The Pink Drive" campaign took bronze at the Goafest's Abby awards. Story

> Takeda and Affymax ($AFFY) have terminated their collaboration and license agreement on anemia drug Omontys and will withdraw their NDA. More (sub. req.)

> Roche's ($RHHBY) Gazyvaro has won Swiss approval for the therapy of patients with previously untreated chronic lymphocytic leukemia (CLL). Release

> U.K. cost watchdog NICE has given its recommendation to Sucampo Pharmaceuticals' constipation med, Amitiza. Release

> Boehringer Ingelheim has earned The Information Standard certification, commissioned by England's National Health Service, for the quality of its healthcare information. Report

And Finally... U.S. submission stumbled at the Lions Health Festival. More

Suggested Articles

A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.

Sanofi and Regeneron recently debuted an unbranded awareness and education campaign around type 2 inflammation and its connections across conditions.

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.